表紙
市場調查報告書

OTC (Over-the-Counter) 止痛藥的全球市場:2020年∼2024年

Global Over the Counter (OTC) Analgesics Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 934872
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
OTC (Over-the-Counter) 止痛藥的全球市場:2020年∼2024年 Global Over the Counter (OTC) Analgesics Market 2020-2024
出版日期: 2020年05月04日內容資訊: 英文 120 Pages
簡介

全球OTC (Over-the-Counter) 止痛藥市場在2020年∼2024年的預測期間內,預計將以6%的年複合成長率增長,達到58億5,000萬美元的規模。市場成長的主要因素有疼痛相關症狀的盛行率增加和OTC止痛藥的銷售增加。

本報告提供全球OTC (Over-the-Counter) 止痛藥市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年∼2024年的預測

波特的五力分析

各類型市場區隔

  • 市場區隔
  • 各類型比較:市場規模、預測(2019年∼2024年)
  • 內服藥物
  • 外用藥
  • 各類型的市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模、預測(2019年∼2024年)
  • 北美
  • 亞洲
  • 歐洲
  • 其他地區
  • 主要國家
  • 各地區的市場機會

成長要素,課題,及趨勢

  • 市場成長要素
  • 交易量的成長要素-需求主導型成長
  • 交易量的成長要素-供給主導型成長
  • 交易量的成長要素-外部要素
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 業者情勢
  • 形勢的創新

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Bayer AG
  • Cipla Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Perrigo Co. Plc
  • Pfizer Inc.
  • Piramal Enterprises Ltd.
  • Reckitt Benckiser Group Plc
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.

附錄

目錄
Product Code: IRTNTR43442

Technavio has been monitoring the over the counter (OTC) analgesics market and it is poised to grow by $ 5.85 bn during 2020-2024 progressing at a CAGR of 6% during the forecast period. Our reports on over the counter (OTC) analgesics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of pain-related conditions and growing number of launches of OTC analgesics. In addition, increasing prevalence of pain-related conditions is anticipated to boost the growth of the market as well.

The over the counter (OTC) analgesics market analysis includes type segment and geographic landscapes

Technavio's ‘ over the counter (OTC) analgesics market ’ is segmented as below:

By Type:

  • Internal OTC analgesics
  • external OTC analgesics

By Geographic Landscape:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies growing number of merger and acquisition (M&A) activities as one of the prime reasons driving the over the counter (OTC) analgesics market growth during the next few years.

"Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our over the counter (OTC) analgesics market covers the following areas:

  • Over the counter (OTC) analgesics market sizing
  • Over the counter (OTC) analgesics market forecast
  • Over the counter (OTC) analgesics market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading over the counter (OTC) analgesics market vendors that include Bayer AG, Cipla Inc., GlaxoSmithKline Plc, Johnson & Johnson, Perrigo Co. Plc, Pfizer Inc., Piramal Enterprises Ltd., Reckitt Benckiser Group Plc, Sanofi, and Sun Pharmaceutical Industries Ltd.. Also, the over the counter (OTC) analgesics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Internal - Market size and forecast 2019-2024
  • External - Market size and forecast 2019-2024
  • Market opportunity by Type

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Bayer AG
  • Cipla Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Perrigo Co. Plc
  • Pfizer Inc.
  • Piramal Enterprises Ltd.
  • Reckitt Benckiser Group Plc
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ billion)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Type - Market share 2019-2024 (%)
  • 22: Comparison by Type
  • 23: Internal - Market size and forecast 2019-2024 ($ billion)
  • 24: Internal - Year-over-year growth 2019-2024 (%)
  • 25: External - Market size and forecast 2019-2024 ($ billion)
  • 26: External - Year-over-year growth 2019-2024 (%)
  • 27: Market opportunity by Type
  • 28: Customer landscape
  • 29: Market share by geography 2019-2024 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2019-2024 ($ billion)
  • 32: North America - Year-over-year growth 2019-2024 (%)
  • 33: Asia - Market size and forecast 2019-2024 ($ billion)
  • 34: Asia - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ billion)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: ROW - Market size and forecast 2019-2024 ($ billion)
  • 38: ROW - Year-over-year growth 2019-2024 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ billion)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Bayer AG - Overview
  • 48: Bayer AG - Business segments
  • 49: Bayer AG - Key offerings
  • 50: Bayer AG - Key customers
  • 51: Bayer AG - Segment focus
  • 52: Cipla Inc. - Overview
  • 53: Cipla Inc. - Business segments
  • 54: Cipla Inc. - Key offerings
  • 55: Cipla Inc. - Key customers
  • 56: Cipla Inc. - Segment focus
  • 57: GlaxoSmithKline Plc - Overview
  • 58: GlaxoSmithKline Plc - Business segments
  • 59: GlaxoSmithKline Plc - Key offerings
  • 60: GlaxoSmithKline Plc - Key customers
  • 61: GlaxoSmithKline Plc - Segment focus
  • 62: Johnson & Johnson - Overview
  • 63: Johnson & Johnson - Business segments
  • 64: Johnson & Johnson - Key offerings
  • 65: Johnson & Johnson - Key customers
  • 66: Johnson & Johnson - Segment focus
  • 67: Perrigo Co. Plc - Overview
  • 68: Perrigo Co. Plc - Business segments
  • 69: Perrigo Co. Plc - Key offerings
  • 70: Perrigo Co. Plc - Key customers
  • 71: Perrigo Co. Plc - Segment focus
  • 72: Pfizer Inc. - Overview
  • 73: Pfizer Inc. - Business segments
  • 74: Pfizer Inc. - Key offerings
  • 75: Pfizer Inc. - Key customers
  • 76: Pfizer Inc. - Segment focus
  • 77: Piramal Enterprises Ltd. - Overview
  • 78: Piramal Enterprises Ltd. - Business segments
  • 79: Piramal Enterprises Ltd. - Key offerings
  • 80: Piramal Enterprises Ltd. - Key customers
  • 81: Piramal Enterprises Ltd. - Segment focus
  • 82: Reckitt Benckiser Group Plc - Overview
  • 83: Reckitt Benckiser Group Plc - Business segments
  • 84: Reckitt Benckiser Group Plc - Key offerings
  • 85: Reckitt Benckiser Group Plc - Key customers
  • 86: Reckitt Benckiser Group Plc - Segment focus
  • 87: Sanofi - Overview
  • 88: Sanofi - Business segments
  • 89: Sanofi - Key offerings
  • 90: Sanofi - Key customers
  • 91: Sanofi - Segment focus
  • 92: Sun Pharmaceutical Industries Ltd. - Overview
  • 93: Sun Pharmaceutical Industries Ltd. - Business segments
  • 94: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 95: Sun Pharmaceutical Industries Ltd. - Key customers
  • 96: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations